Humacyte's ownership structure comprises a diverse mix of institutional healthcare funds, specialized venture capital firms, corporate insiders, and public retail investors. Prominent institutional asset managers, specialized life sciences investment funds, and strategic partners hold significant blocks of common stock, aligning institutional backing with the long-term clinical advancement and commercialization of its regenerative tissue platform.